Synlett 2013; 24(3): 301-304
DOI: 10.1055/s-0032-1317554
cluster
© Georg Thieme Verlag Stuttgart · New York

Development of a Scalable Synthesis of a VEGFR Inhibitor

Ying Chen*
a   Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA   Fax: +1(805)3754531   Email: ying@amgen.com   Email: scui@amgen.com   Email: mfaul@amgen.com
,
Richard D. Crockett
a   Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA   Fax: +1(805)3754531   Email: ying@amgen.com   Email: scui@amgen.com   Email: mfaul@amgen.com
,
Xin Wang
b   Isis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010, USA
,
Robert D. Larsen
c   Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, TX 76134, USA
,
Sheng Cui*
a   Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA   Fax: +1(805)3754531   Email: ying@amgen.com   Email: scui@amgen.com   Email: mfaul@amgen.com
,
Margaret M. Faul*
a   Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA   Fax: +1(805)3754531   Email: ying@amgen.com   Email: scui@amgen.com   Email: mfaul@amgen.com
› Author Affiliations
Further Information

Publication History

Received: 27 September 2012

Accepted after revision: 19 October 2012

Publication Date:
16 November 2012 (online)


Abstract

Process development and salt selection for a novel ­VEGFR inhibitor are described. The overall convergent synthesis involved coupling of three key fragments, 2-chloronicotinoyl chloride, 4-isopropyl-3-methylaniline and 7-aminoisoquinoline. A cost-effective and scalable synthesis of 7-aminoisoquinoline was also achieved. A transition-metal-free SNAr process enabled the final C–N coupling to afford the target molecule. A phosphate form of the drug substance with improved physical properties was selected for further development and the corresponding crystallization process was subsequently developed. Overall, a robust six-step route was developed and demonstrated on multikilogram scales affording the target compound in >30% yield and high purity (>99%).

Supporting Information

 
  • References

  • 1 Holmes K, Roberts OL, Thomas AM, Cross MJ. Cell. Signal. 2007; 19: 2003
  • 2 Ivy SP, Wick JY, Kaufman BM. Nat. Rev. Clin. Oncol. 2009; 6: 569 ; and references therein
  • 3 Yuan C, Yang K, Vanderplas S, Riahi B, Potashman M, Patel VF, Nomak R, Li A, Huang Q, Harmange J, Askew BC. Int. Appl. PCT WO 2006012374, 2006
  • 4 Pictet A, Spengler T. Ber. Dtsch. Chem. Ges. 1911; 44: 2030
    • 5a Wasley J, Rosenthal GJ, Sun X, Strong S, Qiu J. Int. Appl. PCT WO 2010019903, 2010
    • 5b Jiang R, Duckett D, Chen W, Habel J, Ling Y, LoGrasso P, Kamenecka TM. Bioorg. Med. Chem. Lett. 2007; 17: 6378
    • 6a Askin D, Angst C, Danishefsky S. J. Org. Chem. 1987; 52: 622
    • 6b Shi J, Manolikakes G, Yeh C, Guerrero C, Shenvi R, Shigehisa H, Baran P. J. Am. Chem. Soc. 2011; 133: 8014
    • 7a Lundren R, Sappong-Kumankumah A, Stradiotto M. Chem.–Eur. J. 2010; 16: 1683
    • 7b Old DW, Wolfe JP, Buchwald SL. J. Am. Chem. Soc. 1998; 120: 9722
    • 7c Shen QL, Shekhar S, Stambuli JP, Hartwig JF. Angew. Chem. Int. Ed. 2005; 117: 1395
    • 7d Anderson KW, Tundel RE, Ikawa T, Altman RA, Buchwald SL. Angew. Chem. Int. Ed. 2006; 45: 6523
  • 8 Compound 17 was isolated and its structure was determined by NMR studies.
  • 9 Kosugi Y, Itoho K, Okazaki H, Yanai T. J. Org. Chem. 1995; 60: 5690